Group calls for concise, user-friendly drug info

Share this article:

Prescription drug information for patients should be confined to a single, concise document, according to a National Consumers League (NCL) petition filed with the FDA.

“Patients [filling prescriptions] do not need to receive multiple and lengthy pieces of paper that are often redundant and may even contain conflicting information,” said Sally Greenberg, executive director of the NCL, in a statement.

The petition, signed by several national healthcare organizations such as the National Association of Chain Drug Stores, the National Community Pharmacists Association, the National Alliance for Caregivers, and others, suggests that an “FDA-approved, concise, plain language, single patient document” could supplant the myriad patient package inserts, pharmacy medication guides, consumer medication information documents and full professional labeling.

The current information supplied to patients by pharmacies is the result of several FDA legal requirements, or varied, informal interpretations of said requirements, according to the NCL. Some of the regulations are antiquated, or weren't intended for consumers.

“It is important that patients receive clear, useful information in plain language with their prescription drugs,” said Greenberg in the statement. “They should be able to talk to their pharmacist about potential interactions, how to take their medicine and what side effects to expect."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...